Phreesia, Inc. PHR
13.13 USD 0.00 (+0.00%)
At closeNov 11, 2026, 9:05 AM EST
12.61 -0.52 -3.96%
Pre-market · Nov 11, 9:05 AM ET
Day range unavailable
7.77 52-week range 23.31
- YTD
- -22.40%
- 1 year
- -42.29%
News
benzinga.com JP Morgan Downgrades Phreesia to Underweight, Announces $13 Price Target JP Morgan analyst Alexei Gogolev downgrades Phreesia (NYSE:PHR) from Neutral to Underweight and announces $13 price target.
businesswire.com Phreesia Sets Release Date for Fiscal Third Quarter 2027 Results ALL-REMOTE COMPANY/WILMINGTON, Del.--(BUSINESS WIRE)--Phreesia, Inc. (NYSE: PHR) will release its fiscal third quarter 2027 financial results after the close of market trading on Wednesday, Dec. 2,…
benzinga.com Barclays Maintains Equal-Weight on Phreesia, Raises Price Target to $11 Barclays analyst Glen Santangelo maintains Phreesia (NYSE:PHR) with a Equal-Weight and raises the price target from $10 to $11.
benzinga.com Argenx, Caribou Biosciences And Other Big Stocks Moving Lower In Thursday’s Pre-Market Session U.S. stock futures fell, with Dow futures down 450 points. Argenx sank 8.7% after a Sjögren’s trial was halted for futility; others also slid.
benzinga.com DA Davidson Maintains Buy on Phreesia, Lowers Price Target to $13 DA Davidson analyst Clark Wright maintains Phreesia (NYSE:PHR) with a Buy and lowers the price target from $14 to $13.- benzinga.com Baird Maintains Neutral on Phreesia, Raises Price Target to $11 Baird analyst Joseph Vruwink maintains Phreesia (NYSE:PHR) with a Neutral and raises the price target from $10 to $11.
- benzinga.com Phreesia Files Shelf Prospectus For Offering; Size Not Disclosed https://www.sec.gov/Archives/edgar/data/1412408/000162828026060497/phreesia-sx3asr2026.htm
benzinga.com These Analysts Revise Their Forecasts On Phreesia After Q2 Results Phreesia's Q2 EPS missed estimates, while sales beat. FY27 guidance held; shares fell 5.6%. Analysts kept bullish targets, Wells Fargo raised to $10.
benzinga.com Wells Fargo Maintains Equal-Weight on Phreesia, Raises Price Target to $10 Wells Fargo analyst Stan Berenshteyn maintains Phreesia (NYSE:PHR) with a Equal-Weight and raises the price target from $9 to $10.
benzinga.com Transcript: Phreesia Q2 2027 Earnings Conference Call Phreesia (NYSE:PHR) reported second-quarter financial results on Wednesday. The transcript from the company's second-quarter earnings call has been provided below. This content is powered by Benzinga…
benzinga.com 12 Health Care Stocks Moving In Wednesday's After-Market Session Gainers Gelteq (NASDAQ:GELS) stock moved upwards by 20.3% to $0.84 during Wednesday's after-market session. The company's market cap stands at $5.6 million. Nyxoah (NASDAQ:NYXH) shares increased by…- benzinga.com Phreesia Affirms FY2027 Sales Guidance of $510.000M-$520.000M vs $515.008M Est Phreesia (NYSE:PHR) affirms FY2027 sales outlook from $510.000 million-$520.000 million to $510.000 million-$520.000 million vs $515.008 million estimate.
- benzinga.com Phreesia Q2 EPS $0.03 Misses $0.10 Estimate, Sales $129.458M Beat $129.069M Estimate Phreesia (NYSE:PHR) reported quarterly earnings of $0.03 per share which missed the analyst consensus estimate of $0.10 by 70 percent. This is a 200 percent increase over earnings of $0.01 per share…
benzinga.com 10 Health Care Stocks Whale Activity In Today’s Session This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity…- benzinga.com Truist Securities Maintains Hold on Phreesia, Raises Price Target to $12 Truist Securities analyst Jailendra Singh maintains Phreesia (NYSE:PHR) with a Hold and raises the price target from $11 to $12.
- benzinga.com Citigroup Maintains Neutral on Phreesia, Raises Price Target to $12 Citigroup analyst Daniel Grosslight maintains Phreesia (NYSE:PHR) with a Neutral and raises the price target from $10 to $12.
- benzinga.com Canaccord Genuity Maintains Buy on Phreesia, Lowers Price Target to $16 Canaccord Genuity analyst Richard Close maintains Phreesia (NYSE:PHR) with a Buy and lowers the price target from $22 to $16.
benzinga.com 12 Health Care Stocks Moving In Thursday's Pre-Market Session 
benzinga.com Market-Moving News for May 28th SNOW: 38% | Snowflake shares are trading higher after the company reported better-than-expected Q1 financial results. Also, the company announced it signed a multi-year strategic collaboration…
benzinga.com Why Phreesia Shares Are Trading Higher By 19%; Here Are 20 Stocks Moving Premarket Phreesia (NYSE: PHR) shares rose in pre-market trading after better-than-expected sales results. Other gainers include Snowflake, Genius Group, and Astrotech.- benzinga.com Phreesia Q1 2027 Earnings Call Transcript
- benzinga.com 12 Health Care Stocks Moving In Wednesday's After-Market Session
- benzinga.com Phreesia Affirms FY2027 Sales Guidance of $510.000M-$520.000M vs $515.698M Est Phreesia (NYSE:PHR) affirms FY2027 sales outlook from $510.000 million-$520.000 million to $510.000 million-$520.000 million vs $515.698 million estimate.
benzinga.com Phreesia Q1 EPS $0.05, Inline, Sales $130.935M Beat $130.128M Estimate Phreesia (NYSE:PHR) reported quarterly earnings of $0.05 per share which met the analyst consensus estimate. This is a 171.43 percent increase over losses of $(0.07) per share from the same period…- benzinga.com Wells Fargo Downgrades Phreesia to Equal-Weight, Lowers Price Target to $9 Wells Fargo analyst Stan Berenshteyn downgrades Phreesia (NYSE:PHR) from Overweight to Equal-Weight and lowers the price target from $15 to $9.
- benzinga.com Barclays Downgrades Phreesia to Equal-Weight, Lowers Price Target to $10 Barclays analyst Glen Santangelo downgrades Phreesia (NYSE:PHR) from Overweight to Equal-Weight and lowers the price target from $24 to $10.
- benzinga.com Phreesia Implements Restructuring Plan, Eliminates ~220 Positions To Reduce Operating Expenses And Align Costs With Business Priorities; Expects Plan Costs To Be Immaterial And Incurred In Fiscal Year 2027 On May 7, 2026, Phreesia, Inc. (the "Company") implemented a restructuring plan intended to reduce operating expenses and better align the Company's cost structure with its current business…
- benzinga.com Keybanc Maintains Overweight on Phreesia, Lowers Price Target to $12 Keybanc analyst Brandon Nispel maintains Phreesia (NYSE:PHR) with a Overweight and lowers the price target from $15 to $12.
- benzinga.com Citigroup Downgrades Phreesia to Neutral, Lowers Price Target to $10 Citigroup analyst Daniel Grosslight downgrades Phreesia (NYSE:PHR) from Buy to Neutral and lowers the price target from $25 to $10.
- benzinga.com 12 Health Care Stocks Moving In Tuesday's Intraday Session
benzinga.com JP Morgan Downgrades Phreesia to Neutral, Lowers Price Target to $16 JP Morgan analyst Alexei Gogolev downgrades Phreesia (NYSE:PHR) from Overweight to Neutral and lowers the price target from $24 to $16.
benzinga.com This Rockwell Automation Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday Top Wall Street analysts changed outlook on top names. Needham downgrades CNTA, Baird downgrades PHR.
benzinga.com This Shake Shack Analyst Is No Longer Bearish; Here Are Top 2 Upgrades For Monday 
benzinga.com Truist Securities Downgrades Phreesia to Hold, Lowers Price Target to $11 Truist Securities analyst Jailendra Singh downgrades Phreesia (NYSE:PHR) from Buy to Hold and lowers the price target from $24 to $11.
benzinga.com These Analysts Slash Their Forecasts On Phreesia Following Q4 Results Phreesia (PHR) reports mixed Q4 results, lowers FY27 sales outlook due to reduced visibility. Shares drop 28.6%. Analysts adjust price targets.- benzinga.com Stephens & Co. Maintains Overweight on Phreesia, Lowers Price Target to $20 Stephens & Co. analyst Jeff Garro maintains Phreesia (NYSE:PHR) with a Overweight and lowers the price target from $32 to $20.
- benzinga.com Canaccord Genuity Maintains Buy on Phreesia, Lowers Price Target to $22 Canaccord Genuity analyst Richard Close maintains Phreesia (NYSE:PHR) with a Buy and lowers the price target from $33 to $22.
benzinga.com Bicara Therapeutics To Rally Around 121%? Here Are 10 Top Analyst Forecasts For Tuesday Top analysts changed outlook on top names. See all changes on analyst ratings page. BTIG & HCW cut price targets, Needham & BMO raised, Baird bcut.
benzinga.com BMO Capital Maintains Outperform on Phreesia, Lowers Price Target to $14 BMO Capital analyst Sean Dodge maintains Phreesia (NYSE:PHR) with a Outperform and lowers the price target from $32 to $14.- benzinga.com Baird Downgrades Phreesia to Neutral, Lowers Price Target to $10 Baird analyst Joseph Vruwink downgrades Phreesia (NYSE:PHR) from Outperform to Neutral and lowers the price target from $25 to $10.
benzinga.com Why Is Phreesia Stock Sinking Tuesday? Phreesia (PHR) stock plunges 26% in premarket after lowering its FY2027 revenue outlook due to softening pharma spending. Get the details.
benzinga.com 12 Health Care Stocks Moving In Tuesday's Pre-Market Session 
benzinga.com Phreesia, Service Properties Trust, Inventiva And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session U.S. stock futures rise on Tuesday with Dow futures up 400 points. Phreesia shares fall 26.5% in pre-market after mixed Q4 results and lower sales guidance. Other stocks also decline.- benzinga.com Needham Maintains Buy on Phreesia, Lowers Price Target to $14 Needham analyst Ryan MacDonald maintains Phreesia (NYSE:PHR) with a Buy and lowers the price target from $35 to $14.
benzinga.com Why Virgin Galactic Shares Are Trading Higher By 6%; Here Are 20 Stocks Moving Premarket Virgin Galactic reported Q4 revenue of $312,000, missing estimates, but beat EPS expectations. Its second SpaceShip is expected to enter service soon, causing a 6% jump in pre-market trading. Other…- benzinga.com 12 Health Care Stocks Moving In Monday's After-Market Session
- benzinga.com Phreesia Lowers FY2027 Sales Guidance from $545.000M-$559.000M to $510.000M-$520.000M Phreesia (NYSE:PHR) lowers FY2027 sales outlook from $545.000 million-$559.000 million to $510.000 million-$520.000 million.
- benzinga.com Phreesia Q4 EPS $0.02 Misses $0.07 Estimate, Sales $127.067M Beat $126.617M Estimate Phreesia (NYSE:PHR) reported quarterly earnings of $0.02 per share which missed the analyst consensus estimate of $0.07 by 70.59 percent. This is a 118.18 percent increase over losses of $(0.11) per…
benzinga.com Top Wall Street Forecasters Revamp Phreesia Expectations Ahead Of Q4 Earnings Phreesia, Inc. will release Q4 earnings on 3/30. Analysts expect 7 cents per share, down from 18 cents last year. Latest ratings show mixed opinions.
benzinga.com Earnings Scheduled For March 30, 2026